drugset / Trial / NCT00474058

Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine

NCT00474058

Phase 3 Completed 287 enrolled UCB Pharma
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this trial is to assess the effects of transdermal rotigotine on the control of early morning motor function and sleep disorders compared to placebo in subjects with idiopathic Parkinsons´s disease. In addition, effects of rotigotine on specific nocturnal and non-motor symptoms of Parkinson´s disease will be evaluated.

Timeline

Start
2007-05
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Rotigotine Unknown 2 mg Other
Subject Rotigotine Unknown 4 mg Other
Subject Rotigotine Unknown 6 mg Other
Subject Rotigotine Unknown 8 mg Other
Subject Rotigotine Unknown 16 mg Other

Indications